DelveInsight’s “Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Non-Radiographic Axial Spondyloarthritis Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Non-Radiographic Axial Spondyloarthritis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Non-Radiographic Axial Spondyloarthritis (nr-AxSpA): An Overview
Axial spondyloarthritis (axSpA) is an umbrella term for inflammatory arthritis types that primarily affects the spine and the sacroiliac (SI) joints that connect the lower spine to the pelvis, resulting in pain in the lower back, hips, and buttocks. There are two subtypes of axSpA: Non-radiographic axial spondyloarthritis (nr-axSpA) and Ankylosing spondylitis (AS).
“Non-radiographic” means that the disease causes symptoms, but damage to the joints is not visible on X-ray. When changes to the vertebrae (the bones of the spine) or SI joints do not show any X-ray changes, it is known as nr-axSpA. Once the joints are affected by an X-ray, a person can be diagnosed with AS.
Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Market Key Facts
As per the National Axial Spondyloarthritis Society (NASS), the prevalence of nr-axSpA versus AS is thought to be a ratio of 1:1. Around 7 in 10 people with nr-axSpA have visible inflammation in the sacroiliac joints or the spine when an MRI of the back is carried out. Whereas, about 3 in 10 may not have any inflammation visible on MRI despite back pain symptoms.
According to (Slobodin and Eshed, 2015) the prevalence of nr-axSpA is similar to that of AS, but the former has a higher female preponderance. The rate of progression of nrAxSpA to the radiographic stage of disease (AS) ranges from 10% to 20% over 2 years.
According to DelveInsight, females are more affected than males in the case of Non-radiographic axial spondyloarthritis.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Non-Radiographic Axial Spondyloarthritis market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives complete detail of the Non-Radiographic Axial Spondyloarthritis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.
Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.
Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non-Radiographic Axial Spondyloarthritis market or expected to get launched during the study period. The analysis covers Non-Radiographic Axial Spondyloarthritis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Non-Radiographic Axial Spondyloarthritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/non-radiographic-axial-spondyloarthritis-nr-axspa-market
Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Therapeutics Analysis
Currently, there is no exact cure, so the treatment focuses on helping the patient to feel better. Nonsteroidal anti-inflammatory drugs (NSAIDs) and physical therapy are generally effective.
Companies worldwide are persistently working toward developing new treatment therapies for Non-Radiographic Axial Spondyloarthritis (nr-AxSpA). The emerging therapies are expected to launch in the coming years and are anticipated to change the treatment dynamics in the coming years.
Some of the key companies in the Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) market include:
UCB Biopharma SR
Sun Pharma Global FZE
And many others.
Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Therapies covered in the report include:
And many others.
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/non-radiographic-axial-spondyloarthritis-nr-axspa-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Non-Radiographic Axial Spondyloarthritis Competitive Intelligence Analysis
4. Non-Radiographic Axial Spondyloarthritis Market Overview at a Glance
5. Non-Radiographic Axial Spondyloarthritis Disease Background and Overview
6. Non-Radiographic Axial Spondyloarthritis Patient Journey
7. Non-Radiographic Axial Spondyloarthritis Epidemiology and Patient Population
8. Non-Radiographic Axial Spondyloarthritis Treatment Algorithm, Current Treatment, and Medical Practices
9. Non-Radiographic Axial Spondyloarthritis Unmet Needs
10. Key Endpoints of Non-Radiographic Axial Spondyloarthritis Treatment
11. Non-Radiographic Axial Spondyloarthritis Marketed Products
12. Non-Radiographic Axial Spondyloarthritis Emerging Therapies
13. Non-Radiographic Axial Spondyloarthritis Seven Major Market Analysis
14. Attribute Analysis
15. Non-Radiographic Axial Spondyloarthritis Market Outlook (7 major markets)
16. Non-Radiographic Axial Spondyloarthritis Access and Reimbursement Overview
17. KOL Views on the Non-Radiographic Axial Spondyloarthritis Market.
18. Non-Radiographic Axial Spondyloarthritis Market Drivers
19. Non-Radiographic Axial Spondyloarthritis Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/non-radiographic-axial-spondyloarthritis-nr-axspa-market
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Latest Healthcare Report by DelveInsight
Campylobacter Infections Market
“Campylobacter Infections Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Campylobacter Infections Market size, share, and trends in the 7MM. Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States